[go: up one dir, main page]

DK0858328T3 - Stabile præparater indeholdende N-propargyl-1-aminoindan - Google Patents

Stabile præparater indeholdende N-propargyl-1-aminoindan

Info

Publication number
DK0858328T3
DK0858328T3 DK96930344T DK96930344T DK0858328T3 DK 0858328 T3 DK0858328 T3 DK 0858328T3 DK 96930344 T DK96930344 T DK 96930344T DK 96930344 T DK96930344 T DK 96930344T DK 0858328 T3 DK0858328 T3 DK 0858328T3
Authority
DK
Denmark
Prior art keywords
pct
aminoindan
propargyl
preparations containing
sec
Prior art date
Application number
DK96930344T
Other languages
Danish (da)
English (en)
Inventor
Peskin Tirtsah Berger
Fanny Caciularu
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11068003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0858328(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK0858328T3 publication Critical patent/DK0858328T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
DK96930344T 1995-09-20 1996-09-18 Stabile præparater indeholdende N-propargyl-1-aminoindan DK0858328T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11535795A IL115357A (en) 1995-09-20 1995-09-20 Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
PCT/IL1996/000115 WO1997012583A2 (fr) 1995-09-20 1996-09-18 Compositions stables contenant du n-propargyl-1-aminoindane

Publications (1)

Publication Number Publication Date
DK0858328T3 true DK0858328T3 (da) 2007-09-03

Family

ID=11068003

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96930344T DK0858328T3 (da) 1995-09-20 1996-09-18 Stabile præparater indeholdende N-propargyl-1-aminoindan

Country Status (13)

Country Link
US (1) US6126968A (fr)
EP (1) EP0858328B1 (fr)
JP (1) JP4108750B2 (fr)
AT (1) ATE362755T1 (fr)
AU (1) AU728524B2 (fr)
CA (1) CA2232310C (fr)
DE (1) DE69637096T2 (fr)
DK (1) DK0858328T3 (fr)
ES (1) ES2287940T3 (fr)
HU (1) HU225859B1 (fr)
IL (1) IL115357A (fr)
PT (1) PT858328E (fr)
WO (1) WO1997012583A2 (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) * 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP1242066B1 (fr) 1999-10-27 2006-06-28 Teva Pharmaceutical Industries Ltd. Utilisation de derives de 1-aminoindan pour le traitement de la manie liee a la psychose maniacod pressive
EP2526944B1 (fr) * 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Utilisation de rasagiline, avec ou sans riluzole, pour traiter la sclérose latérale amyotrophique
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
EP1778196A4 (fr) * 2004-07-26 2008-12-17 Teva Pharma Dosages pharmaceutiques contenant de la rasagiline
EP1729735B1 (fr) * 2004-11-10 2007-06-27 Teva Pharmaceutical Industries Ltd. Procede de production de formes dosifiees solides comprimees adapte a des medicaments de faible solubilite aqueuse et formes dosifiees solides comprimees ainsi obtenues
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
ATE521343T1 (de) * 2004-11-24 2011-09-15 Teva Pharma Im mund zerfallende zusammensetzungen von rasagilin
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2596664A1 (fr) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries Ltd. Therapie combinee avec de l'acetate de glatiramere et de rasagiline destinee au traitement de la sclerose en plaques
KR20140103356A (ko) * 2005-02-23 2014-08-26 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
EP1954667B1 (fr) * 2005-11-17 2017-02-08 Teva Pharmaceutical Industries Ltd Procedes de separation d amino-indanes propargyles
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
EP1956904B1 (fr) 2005-12-09 2017-04-12 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Ladostigil a faible dose pour le traitement du déficit cognitif léger
EP1991214B1 (fr) 2006-02-21 2015-08-05 Teva Pharmaceutical Industries, Ltd. Utilisation de rasagiline pour traiter une atrophie multisystématisée
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
EP2007369A4 (fr) 2006-04-03 2009-07-01 Teva Pharma Utilisation de rasagiline pour le traitement du syndrome des jambes sans repos
DE202006020710U1 (de) 2006-05-09 2009-12-31 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit Rosiglitazonmaleat
EP1892233A1 (fr) * 2006-08-18 2008-02-27 Ratiopharm GmbH De nouveaux sels de la substance active rasagiline
WO2008076315A1 (fr) * 2006-12-14 2008-06-26 Teva Pharmaceutical Industries, Ltd. Sel de tannate de rasagiline
EA016820B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
EP1987816A1 (fr) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate d'un sel de rasagiline en combinaison avec un agent inactive soluble dans l'eau
EP2194780A4 (fr) * 2007-09-05 2010-10-27 Teva Pharma Procédé pour traiter le glaucome avec la rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
US20110117200A1 (en) * 2008-03-31 2011-05-19 Actavis Group Ptc Ehf Rasagiline mesylate particles and process for the preparation thereof
JP2011522892A (ja) * 2008-06-13 2011-08-04 テバ ファーマシューティカル インダストリーズ リミティド パーキンソン病緩和のためのラサギリン
CA2727021A1 (fr) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Procede de purification de la base de la rasagiline
WO2009154777A2 (fr) 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Processus de préparation et de séchage de rasagiline base solide
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
EP2218444A3 (fr) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Formulation de rasagiline à libération retardée
CA2754089A1 (fr) 2009-03-05 2010-09-10 Sandoz Ag Composition pharmaceutique contenant du (1r)-methanesulfonate de 1h-inden-1-amine-2,3-dihydro-n-2-propynyle
RS53504B1 (sr) 2009-07-09 2015-02-27 Ratiopharm Gmbh Soli razagilina i njihovi farmaceutski preparati
CN102048717B (zh) † 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2939669A1 (fr) 2009-12-22 2015-11-04 Teva Pharmaceutical Industries, Ltd. 3-céto-n-propargyl-1-aminoindane
WO2011139420A2 (fr) 2010-04-30 2011-11-10 Teikoku Pharma Usa, Inc. Compositions transdermiques de propynylaminoindane
EP2389927A1 (fr) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Formulations pharmaceutiques de rasagiline
AU2011282716A1 (en) 2010-07-27 2013-03-14 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
KR101853082B1 (ko) 2011-03-24 2018-04-27 테이코쿠 팔마 유에스에이, 인코포레이티드 활성제층 및 활성제 변환층을 포함하는 경피 조성물
AU2012323351A1 (en) 2011-10-10 2014-05-22 Teva Pharmaceutical Industries Ltd. R(+)-N-methyl-propargyl-aminoindan
KR20140090996A (ko) * 2011-10-10 2014-07-18 테바 파마슈티컬 인더스트리즈 리미티드 R(+)-n-폼일-프로파길-아미노인단
US20130089611A1 (en) * 2011-10-10 2013-04-11 Teva Pharmaceutical Industries, Ltd. Rasagiline citramide
EP2776020B1 (fr) 2011-11-09 2019-09-11 Teikoku Seiyaku Co., Ltd. Méthodes pour le traitement de tumeurs de la peau
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
EP2827848B1 (fr) 2012-03-21 2016-04-27 Synthon BV Compositions pharmaceutiques stables comprenant des sels de la rasiligine
WO2013175493A1 (fr) 2012-04-09 2013-11-28 Cadila Healthcare Limited Compositions pharmaceutiques orales stables
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤
KR20150059177A (ko) 2012-11-02 2015-05-29 테이코쿠 팔마 유에스에이, 인코포레이티드 프로피닐아미노인단 경피 조성물
EP2764862A1 (fr) * 2013-02-06 2014-08-13 Galenicum Health S.L. Comprimés à libération immédiate de l'hémitartrate de rasagiline
ES2524865T1 (es) * 2013-02-06 2014-12-15 Galenicum Health S.L. Composiciones farmacéuticas estables en forma de comprimidos de liberación inmediata
CN115400090A (zh) * 2022-10-09 2022-11-29 北京新领先医药科技发展有限公司 一种雷沙吉兰的口崩片组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2039742A1 (fr) * 1990-04-23 1991-10-24 Andrew B. Dennis Comprimes pour ingredients pharmaceutiques sujets a problemes : composition et mode de preparation
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
CA2214026C (fr) * 1995-03-02 2007-10-16 R.P. Scherer Limited Compositions pharmaceutiques comprenant des inhibiteurs de la monoamine oxydase b

Also Published As

Publication number Publication date
CA2232310A1 (fr) 1997-04-10
ES2287940T3 (es) 2007-12-16
EP0858328B1 (fr) 2007-05-23
HUP9802999A2 (hu) 1999-04-28
DE69637096T2 (de) 2008-01-31
EP0858328A2 (fr) 1998-08-19
HUP9802999A3 (en) 1999-05-28
US6126968A (en) 2000-10-03
ATE362755T1 (de) 2007-06-15
JP4108750B2 (ja) 2008-06-25
IL115357A (en) 2000-01-31
WO1997012583A2 (fr) 1997-04-10
AU728524B2 (en) 2001-01-11
CA2232310C (fr) 2008-01-08
DE69637096D1 (de) 2007-07-05
EP0858328A4 (fr) 2001-07-11
AU6942796A (en) 1997-04-28
WO1997012583A3 (fr) 1997-06-05
IL115357A0 (en) 1995-12-31
HU225859B1 (en) 2007-11-28
JPH11512736A (ja) 1999-11-02
PT858328E (pt) 2007-08-20

Similar Documents

Publication Publication Date Title
DK0858328T3 (da) Stabile præparater indeholdende N-propargyl-1-aminoindan
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
FR2688422B1 (fr)
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
ZA948670B (en) New benzoyl guanidine derivatives,the preparation thereof and their use in pharmaceutical compositions
EP1468679A3 (fr) Composition de tramadol à libération contrôlée
PT881901E (pt) Novas associacoes de principios activos contendo clopidogrel e um agente anti-trombotico
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
CA2203310A1 (fr) Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
IT1272149B (it) Composizione farmeceutiche ad attivita' analgesica
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
CA2152998A1 (fr) Composition pharmaceutique anti-hyperglycemique
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
ZA922910B (en) Heterocylic pharmaceutical compounds preparation and use
ATE246515T1 (de) Verfahren zur herstellung von oralen dosierungsformulierungen enthaltend diclofenac
AU2774292A (en) Toiletries composition
NO950177L (no) Farmakologisk aktive erivater
AU7470098A (en) Antithrombotic agents
ZA965749B (en) Use of allylamines.
AU3749195A (en) Bis-2-aminopyridines, preparation method therefor and use tereof for controlling parasitic infections
KR950700743A (ko) 프로스타사이클린류를 활성성분으로서 함유하는 외용 피부치료제 조성물(dermatologic preparation composition containing prostacyclin as active ingredient)
ATE234096T1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
TW333453B (en) Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases
AU7274198A (en) Antithrombotic agents
JO1750B1 (en) Substituted benzimidazole compounds, practical to prepare and use